Szoptatás Portál ... naprakész információk a szoptatásról

Commentary

Spyros Karras, Themistoklis Tzotzas, Gerasimos E. Krassas
HORMONES 2009, 8(4):254-257

Antithyroid drugs (ATD) are widely used by endocrinologists all over the world for the treatment of Graves’ disease (GD) in the general population and in lactating thyrotoxic mothers. Traditionally, these agents produce minor side effects (rash, fever, urticaria) in 5-10% of the treated patients and major side effects (agranulocytosis, vasculitis, hepatic toxicity) much less frequently. These side effects appear more likely to be dose-related for methimazole (MMI) rather than propylthiouracil (PTU).

Miguel Marcelo Glatstein, Facundo Garcia-Bournissen, Norberto Giglio, Yaron Finkelstein, and Gideon Koren
Can Fam Physician Vol. 55, No. 8, August 2009, pp.797 - 798

QUESTION I have a patient who has hyperthyroidism due to Graves disease. She was taking methimazole but discontinued when she found out she was pregnant. She is currently close to delivery and might require antithyroid therapy in the postpartum period. Can methimazole cross into human milk, and is breastfeeding safe for her infant?